References,Sample size,Interventions,Main race,Female (%),Mean HAMA,Mean age (Year),Attrition rate (%),Sponsor,Follow-up time (weeks),Diagnosis criteria
"Mahableshwarkar et al., 2014",781,placebo,White,65.0,24.4,36.8,23.1,"Takeda Pharmaceutical Company, Ltd",12,dsm-iv
"Mahableshwarkar et al., 2014",781,vortioxetine: 2.5 mg/day,White,69.9,25.3,39.2,23.1,"Takeda Pharmaceutical Company, Ltd",12,dsm-iv
"Mahableshwarkar et al., 2014",781,vortioxetine: 5 mg/day,White,64.1,25.0,37.7,28.8,"Takeda Pharmaceutical Company, Ltd",12,dsm-iv
"Mahableshwarkar et al., 2014",781,vortioxetine: 10 mg/day,White,67.3,25.3,39.8,28.2,"Takeda Pharmaceutical Company, Ltd",12,dsm-iv
"Mahableshwarkar et al., 2014",781,duloxetine: 60 mg/day,White,72.4,25.0,39.5,32.1,"Takeda Pharmaceutical Company, Ltd",12,dsm-iv
